A Review on Brain Metastases Prognostic Scoring Systems | Chapter 9 | New Frontiers in Medicine and Medical Research Vol. 1

 The most prevalent intracranial tumours are brain metastases (BMs), and about 25% of all cancer patients are identified with this poor prognostic illness condition at some point throughout their therapy. The primary prevailing treatment options normally include palliative radiotherapy, chemotherapy, targeted medicines, immunotherapy, optimum supportive care, and surgery in select patients, depending on the possible patient's general well-being status. Previous research has shown that prognostic scoring methods can be used to group BM patients into specific prognostic groups based on realistic combinations of several patient- and tumor-related characteristics. Such frameworks could be effective in accurately predicting survival outcomes and selecting the best-fit treatment option. The goal of this study was to look at the benefits and drawbacks of the widely used on-the-spot prognostic grading systems for BMs, as well as their clinical use.

Author (s) Details

Erkan Topkan
Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey.

Ahmet Kucuk
Mersin City Education and Research Hospital, Radiation Oncology Clinics, Mersin, Turkey.

Duygu Sezen
Department of Radiation Oncology, Koc University, School of Medicine, Istanbul, Turkey.

Sukran Senyurek
Department of Radiation Oncology, Koc University, School of Medicine, Istanbul, Turkey.

Eyub Yasar Aydemir
Department of Radiation Oncology, Koc University, School of Medicine, Istanbul, Turkey.

Nulifer Kilic Durankus
Department of Radiation Oncology, Koc University, School of Medicine, Istanbul, Turkey.

Yasemin Bolukbasi
Department of Radiation Oncology, Koc University, School of Medicine, Istanbul, Turkey.

Berrin Pehlivan
Department of Radiation Oncology, Bahcesehir University, Istanbul, Turkey.

Ugur Selek
Department of Radiation Oncology, Koc University, School of Medicine, Istanbul, Turkey.

View Book :- https://stm.bookpi.org/NFMMR-V1/article/view/2788

Management of Brain Metastases with Preoperative Radiosurgery | Chapter 11 | Highlights on Medicine and Medical Research Vol. 2

Nearly 30 percent to 54 percent of all patients are diagnosed with the most common intracranial tumor brain metastases (BMs) during or after their solid cancer treatment courses. Although the prognosis is extremely poor for BM patients, the estimated median OS is usually less than 7 months. However, nowadays, after the implementation of effective systemic and local therapies, such as surgery and radiotherapy, some patient groups can experience significantly longer survival periods (RT). Neurosurgery, whole-brain RT (WBRT), definitive SRS, postoperative SRS, systemic chemotherapy, targeted therapies, immunotherapy and their various mixtures are currently noteworthy alternatives for the management of BMs. Regarding the local treatment maneuvers, the well-recognized severe neurotoxicity of WBRT and the augmented risk for radionecrosis and leptomeningeal dissemination after postoperative SRS and the ineligibility of certain patients during the postoperative period mandated the search for safer and potentially more effective treatment alternatives for such patients' group. In this regard, it was proposed that the novel preoperative SRS (PO-SRS) should provide at least comparable local control rates with a lower risk of radionecrosis and leptomeningeal spread. This chapter describes the conceivable rationale and available evidence for the new PO-SRS in the management armamentarium for cancer patients who have BMs.

Author (s) Details

Erkan Topkan
Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey.

Ahmet Kucuk
Mersin City Education and Research Hospital, Radiation Oncology Clinics, Mersin, Turkey.

Sukran Senyurek
Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey.

Duygu Sezen
Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey.

Nulifer Kilic Durankus
Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey.

Eyub Yasar Akdemir
Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey.

Esma Didem Ikiz
Department of Radiation Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey.

Yasemin Bolukbasi
Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey.

Berrin Pehlivan
Department of Radiation Oncology, Bahcesehir University, Istanbul, Turkey.

Ugur Selek
Department of Radiation Oncology, School of Medicine, Koc University, Istanbul, Turkey.

View Book :- https://stm.bookpi.org/HMMR-V2/issue/view/20